Homer A. Macapinlac, M.D. - Professor, James E. Anderson Distinguished Professor of Nuclear Medicine, Chair, Department of Nuclear Medicine
Research Interests: Early response evaluation in solid tumors (e.g. lung cancer, lymphoma) using various novel PET tracers in comparison to FDG. Novel theranostic multi-tracer techniques using PET/CT or SPECT/CT for pre-therapy dosimetry/patient selection, alpha/beta therapy and post therapy dose estimates in patients with prostate, neuroendocrine and breast cancer. Novel PET/MR techniques to improve multi-parametric image quantification in early recurrence of prostate cancer.
Yang Lu, M.D., Ph.D. - Associate Professor, Medical Director of Clinical Nuclear Medicine, Department of Nuclear Medicine
Research Interests: Radiomics studies to promote patient care, novel radiotracers and radiopharmaceuticals for molecular imaging and targeted therapy.
Gregory C. Ravizzini, M.D. - Associate Professor, ad interim CABI Medical Director
Research Interests: Pre-clinical and clinical molecular imaging for oncological applications, the development of novel radiopharmaceuticals for imaging and targeted radiotherapy.
Beth A. Chasen, M.D. - Associate Professor
Research Interests: Radiopharmaceuticals as diagnostic and therapeutic agents; novel radiotracer use in clinical operations, image acquisition, and interpretation.
Hubert H. Chuang, M.D., Ph.D. - Associate Professor
Research Interests: PET/CT in patients with Lymphoma, PET/CT imaging response prediction for paraganglioma/pheochromcytoma, plasmacytoma, adrenocortical carcinoma (ACC), malignancy of unknown origin and bone and soft tissue tumors.
Lesley Flynt, M.D. - Assistant Professor
Carlos E. Gonzalez-Lepera, Ph.D. - Professor
Research Interests: Implement and oversee manufacturing of FDA approved PET radiopharmaceuticals; Develop new techniques for cyclotron produced radioisotopes and radiopharmaceuticals.
Elmer B. Santos, M.D., Ph.D. - Assistant Professor
Research Interests: Development and clinical application of new radiotracers and radiotherapies for thyroid, prostate, and neuroendocrine tumors: Clinical use of radioactive anti-human kallikrein 2 antibody for diagnosis and therapy of primary and metastatic prostate cancer; Restoring radioiodine responsiveness by inhibiting Ras/Raf/MEK pathway in RAI-refractory thyroid cancer; Clinical utility of 68Ga-DOTATOC in detecting neuroendocrine tumors.
Franklin C. Wong, M.D., Ph.D., JD, MS, MBA - Professor
Research Interests: Animal tumor model.